CDK4-6 inhibitors in breast cancer: current status and future development

Joan Rou-En Choo1, Soo-Chin Lee1,2

  • 1a Department of Haematology-Oncology , National University Cancer Institute, National University Health System (NUHS) , Singapore , Singapore.

Abstract

Insights

Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) show similar efficacy for hormone-receptor positive metastatic breast cancer. Differences in toxicity and dosing may guide treatment choices, with biomarker research ongoing.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Dysregulation of the cyclin-dependent kinase (CDK) retinoblastoma (Rb)-pathway drives aberrant cellular proliferation in various cancers.
  • Selective CDK4/6 inhibition is a key therapeutic strategy for hormone-receptor positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC).
  • Palbociclib, ribociclib, and abemaciclib are approved CDK4/6 inhibitors for HR+/HER2- MBC treatment.

Purpose of the Study:

  • To compare the pharmacology, clinical efficacy, and toxicity profiles of approved CDK4/6 inhibitors.
  • To discuss challenges in CDK4/6 inhibitor therapy, including biomarker identification, dosing optimization, and combination strategies.
  • To provide an expert opinion on the current landscape and future directions for CDK4/6 inhibitors in HR+/HER2- MBC.

Main Methods:

  • Comprehensive literature review of pharmacology, clinical trials, and toxicity data for palbociclib, ribociclib, and abemaciclib.
  • Comparative analysis of efficacy (progression-free survival) and safety profiles.
  • Discussion of challenges and future research directions based on current evidence.

Main Results:

  • All three CDK4/6 inhibitors demonstrate significant efficacy when combined with endocrine therapy for HR+/HER2- MBC, improving progression-free survival.
  • Clinical efficacy appears comparable across the three agents.
  • Differences in toxicity profiles, dosing schedules, and monitoring requirements exist, potentially influencing clinical selection.

Conclusions:

  • CDK4/6 inhibitors have transformed HR+/HER2- MBC treatment with consistent PFS benefits.
  • Treatment choice may depend on individual drug toxicity, dosing, and patient monitoring.
  • Further research is needed to identify predictive biomarkers and optimize combination therapies for CDK4/6 inhibition.

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Sustainable Development01:43

Sustainable Development

As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.1K
Marcia's Theory of Identity Status01:26

Marcia's Theory of Identity Status

James Marcia's identity status model provides a framework for understanding how adolescents navigate identity formation through varying degrees of exploration and commitment. Marcia's model builds on Erik Erikson's theories of psychosocial development, focusing specifically on how adolescents reconcile individual aspirations with societal expectations. His model describes identity formation as a dynamic process where adolescents move between different states depending on their level...
1.6K
Electrical Current01:10

Electrical Current

Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Current Density01:21

Current Density

The total amount of current flowing through one unit value of a cross-sectional area is referred to as current density. If the current flow is uniform, the amount of current flowing through a conductor is the same at all points along the conductor, even if the conductor area varies. The current density consists of the local magnitude and direction of the charge flow, which varies from point to point. Current density is measured in amperes per meter square, and direction is defined as the net...
5.1K
Eddy Currents01:25

Eddy Currents

Since eddy currents occur only in conductors, magnets can separate metals from other materials. For example, in a recycling center, trash is dumped in batches down a ramp, beneath which lies a powerful magnet. Conductors in the trash are slowed by eddy currents, while nonmetals in the trash move on, separating from the metals. This works for all metals, not just ferromagnetic ones.
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...
2.6K